Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1Endocrine 1

Conditions

Neuroendocrine Tumors 5Carcinoma, Neuroendocrine 5Thyroid Neoplasms 2Adrenocortical Carcinoma 2Vulvar Neoplasms 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Small Cell Lung Carcinoma 1Seminoma 1Sarcoma 1Rare Diseases 1Pseudomyxoma Peritonei 1Pituitary Neoplasms 1Pituitary Diseases 1Pheochromocytoma 1Perivascular Epithelioid Cell Neoplasms 1Penile Neoplasms 1Parathyroid Neoplasms 1Paranasal Sinus Neoplasms 1Paraganglioma 1Paget Disease, Extramammary 1Ovarian Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Histiocytoma, Malignant Fibrous 1

Interventions

pembrolizumab 2Etoposide 2Cisplatin 2veliparib 1taxane 1liposomal doxorubicin 1Vinorelbine 1RRx-001 1Quality of Life 1Podophyllotoxin 1Platinum 1Pemetrexed 1Patient Reported Outcome Measures 1Paclitaxel 1PT-100 dipeptide 1Nivolumab 1Molecular Diagnostic Techniques 1Irinotecan 1Ipilimumab 1Immunotherapy 1Gemcitabine 1Drug Therapy 1Carboplatin 1Biological Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × Ipilimumab × Endocrine × Clear all
NCT03333616 2026-01-21

Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
100 enrolled
EndocrineGenitourinary

Penile Neoplasms, Urogenital Neoplasms, Adrenocortical Carcinoma, Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡